Demographic characteristics of all the 5-year survivors alive at the time of the study (n=573) and for levels 1, 2 and 3 subgroups
| Characteristic | Five-year survivors (n-573) | Level 1(n=86) | Level 2 (n=258) | Level 3 (n=229) | ||||
|---|---|---|---|---|---|---|---|---|
| n | Per cent | n | Per cent | n | Per cent | n | Per cent | |
| Sex | ||||||||
| Male | 303 | 52.9 | 37 | 43 | 137 | 53.1 | 129 | 56.3 |
| Female | 270 | 47.1 | 49 | 57 | 121 | 46.9 | 100 | 43.7 |
| Current age (years) | ||||||||
| 5–9 | 44 | 7.7 | 11 | 12.8 | 15 | 5.8 | 18 | 7.8 |
| 10–14 | 110 | 19.2 | 19 | 22.1 | 56 | 21.7 | 35 | 15.3 |
| 15–19 | 148 | 25.8 | 31 | 36.0 | 66 | 25.6 | 51 | 22.3 |
| 20–24 | 129 | 22.5 | 19 | 22.1 | 51 | 19.8 | 59 | 25.8 |
| 25–29 | 69 | 12.0 | 6 | 7.0 | 30 | 11.6 | 33 | 14.4 |
| 30–34 | 40 | 7.0 | – | – | 16 | 6.2 | 24 | 10.5 |
| 35–39 | 21 | 3.7 | – | – | 15 | 5.8 | 6 | 2.6 |
| 40–44 | 11 | 1.9 | – | – | 8 | 3.1 | 3 | 1.3 |
| 45–49 | 1 | 0.2 | – | – | 1 | 0.4 | – | – |
| Median (range) | 19.4 | 5.1–45.1 | 17.5 | 5.1–28.4 | 19.4 | 8.0–45.1 | 20.1 | 5.6–43.7 |
| Age at diagnosis (years) | ||||||||
| 0–4 | 286 | 49.9 | 54 | 62.8 | 140 | 54.3 | 92 | 40.2 |
| 5–9 | 144 | 25.1 | 16 | 18.6 | 68 | 26.4 | 60 | 26.2 |
| 10–14 | 122 | 21.3 | 15 | 17.4 | 48 | 18.6 | 59 | 25.8 |
| 15–19 | 21 | 3.7 | 1 | 1.2 | 2 | 0.7 | 18 | 7.8 |
| Median (range) | 5.0 | 0–20.9 | 2.9 | 0–15.4 | 4.5 | 0–20.9 | 6.5 | 0–17.5 |
| Time from diagnosis (years) | ||||||||
| 5–9 | 197 | 34.4 | 33 | 38.4 | 80 | 31.0 | 84 | 36.7 |
| 10–14 | 166 | 29.0 | 32 | 37.2 | 76 | 29.5 | 58 | 25.3 |
| 15–19 | 100 | 17.5 | 11 | 12.8 | 38 | 14.7 | 51 | 22.3 |
| 20–24 | 58 | 10.1 | 8 | 9.3 | 30 | 11.6 | 20 | 8.7 |
| 25–29 | 30 | 5.2 | 2 | 2.3 | 16 | 6.2 | 12 | 5.2 |
| 30–34 | 12 | 2.1 | – | – | 10 | 3.9 | 2 | 0.9 |
| 35–39 | 10 | 1.7 | – | – | 8 | 3.1 | 2 | 0.9 |
| Median (range) | 12.4 | 5.0–39.3 | 11.0 | 5.0–26.9 | 13.0 | 5.0–38.4 | 12.9 | 5.0–39.3 |
| DFS (years) | ||||||||
| 0–4 | 36 | 6.3 | 1 | 1.2 | 20 | 7.7 | 15 | 6.5 |
| 5–9 | 198 | 34.5 | 34 | 39.5 | 82 | 31.8 | 82 | 35.8 |
| 10–14 | 160 | 27.9 | 31 | 36.0 | 67 | 26.0 | 62 | 27.1 |
| 15–19 | 84 | 14.7 | 10 | 11.6 | 34 | 13.2 | 40 | 17.5 |
| 20–24 | 57 | 9.9 | 8 | 9.3 | 31 | 12.0 | 18 | 7.9 |
| 25–29 | 19 | 3.4 | 2 | 2.4 | 8 | 3.1 | 9 | 3.9 |
| 30–34 | 17 | 3.0 | – | – | 15 | 5.8 | 2 | 0.9 |
| 35–39 | 2 | 0.3 | – | – | 1 | 0.4 | 1 | 0.4 |
| Median (range) | 11.3 | 0.5–38.3 | 10.9 | 4.4–26.9 | 11.6 | 1.9–36.4 | 11.6 | 0.5–38.3 |
| Time since last seen in hospital-based late effects clinic (years) | ||||||||
| 0–2 | 328 | 57.2 | 31 | 36.0 | 143 | 55.4 | 154 | 67.2 |
| 3–4 | 75 | 13.1 | 16 | 18.6 | 36 | 13.9 | 23 | 10.1 |
| 5–7 | 78 | 13.6 | 20 | 23.3 | 40 | 15.5 | 18 | 7.9 |
| 8–10 | 28 | 5.0 | 6 | 7.0 | 10 | 3.9 | 12 | 5.2 |
| >10 | 41 | 7.1 | 8 | 9.3 | 19 | 7.4 | 14 | 6.1 |
| Unknown | 23 | 4.0 | 5 | 5.8 | 10 | 3.9 | 8 | 3.5 |
| Median (range) | 2.3 | 0–13.1 | 4.5 | 0–12.7 | 2.2 | 0–12.7 | 1.8 | 0–13.1 |
DFS, disease free survival.